Ovintiv Secures $1.2 Billion Two-Year Term Loan to Fund NuVista Acquisition

Reuters
2025.12.01 22:06
portai
I'm PortAI, I can summarize articles.

Ovintiv Inc. has secured a $1.2 billion two-year term loan to finance its acquisition of NuVista Energy Ltd. The loan agreement, signed on November 25, 2025, involves multiple lenders with JPMorgan Chase Bank as the administrative agent. The loan will mature two years after funding, with interest rates based on Ovintiv’s credit ratings. The proceeds will be used to acquire all outstanding NuVista Energy shares not already owned by Ovintiv Canada.

Ovintiv Inc. has entered into a new two-year term credit agreement to finance its acquisition of NuVista Energy Ltd. The agreement, signed on November 25, 2025, allows Ovintiv Canada ULC to borrow up to $1.2 billion, with Ovintiv Inc. acting as guarantor. JPMorgan Chase Bank, N.A., Toronto Branch, is serving as administrative agent for the facility, which involves multiple lenders. The loan will mature two years after funding, with interest rates determined by Ovintiv’s credit ratings. The agreement includes customary covenants and a requirement that Ovintiv’s consolidated debt-to-capitalization ratio not exceed 60%. The proceeds are intended to fund the acquisition of all outstanding NuVista Energy shares not already owned by Ovintiv Canada. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovintiv Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-304036), on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here